MCID: NVS001
MIFTS: 52

Neovascular Glaucoma

Categories: Eye diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Neovascular Glaucoma

MalaCards integrated aliases for Neovascular Glaucoma:

Name: Neovascular Glaucoma 12 58 15 17
Glaucoma, Neovascular 43 71
Secondary Angle-Closure Glaucoma with Rubeosis 12
Glaucoma Neovascular 54

Characteristics:

Orphanet epidemiological data:

58
neovascular glaucoma
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare eye diseases
Developmental anomalies during embryogenesis


External Ids:

Disease Ontology 12 DOID:1687
MeSH 43 D015355
MESH via Orphanet 44 D015355
UMLS via Orphanet 72 C0017609
Orphanet 58 ORPHA94058
UMLS 71 C0017609

Summaries for Neovascular Glaucoma

MalaCards based summary : Neovascular Glaucoma, also known as glaucoma, neovascular, is related to intraocular pressure quantitative trait locus and rubeosis iridis. An important gene associated with Neovascular Glaucoma is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are ERK Signaling and Apoptotic Pathways in Synovial Fibroblasts. The drugs Travoprost and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and b cells, and related phenotypes are glaucoma and visual loss

Related Diseases for Neovascular Glaucoma

Diseases related to Neovascular Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 255)
# Related Disease Score Top Affiliating Genes
1 intraocular pressure quantitative trait locus 31.9 VEGFA TGFB2 PEX19
2 rubeosis iridis 31.6 VEGFA PLG
3 retinal vein occlusion 31.5 VEGFA KDR CXCL8
4 branch retinal artery occlusion 31.2 VEGFA PLG
5 retinal detachment 31.0 VEGFA RS1 FGF2 CXCL8
6 microvascular complications of diabetes 1 30.9 VEGFA TGFB2 FLT1 FGF2 CXCL8
7 central retinal artery occlusion 30.6 VEGFA PLG
8 coats disease 30.6 VEGFA RS1 KDR
9 glaucoma, primary open angle 30.5 TGFB2 SLC6A13 PEX19
10 microvascular complications of diabetes 5 30.2 VEGFA TGFB2 PLG PGF KDR FLT1
11 cataract 30.2 VEGFA TJP1 TGFB2 FGF2 CXCL8
12 background diabetic retinopathy 30.1 VEGFA PGF KDR
13 melanoma, uveal 30.1 VEGFC VEGFA TGFB2 PLG
14 acute closed-angle glaucoma 30.1 PEX19 CIAO3
15 endophthalmitis 30.0 VEGFB VEGFA PLG PGF FLT1 CXCL8
16 moyamoya disease 1 30.0 VEGFA PLG FGF2
17 retinal artery occlusion 29.9 VEGFB VEGFA PLG PGF KDR FLT1
18 hemangioma 29.8 VEGFA KDR FLT1 FGF2
19 macular holes 29.8 VEGFA TGFB2 RS1 PLG CXCL8
20 capillary hemangioma 29.6 VEGFA KDR FLT1 FGF2
21 keratitis, hereditary 29.6 VEGFC VEGFA FLT1 FGF2 CXCL8
22 retinal vascular occlusion 29.3 VEGFB VEGFA PLG PGF KDR FLT1
23 myeloma, multiple 29.2 VEGFA KDR FLT1 FGF2 CXCL8
24 macular retinal edema 29.1 VEGFB VEGFA TJP1 PLG PGF KDR
25 diabetic macular edema 28.8 VEGFC VEGFB VEGFA PGF FLT1 FGF2
26 retinal vascular disease 28.7 VEGFB VEGFA TJP1 PLG PGF KDR
27 eye disease 28.5 VEGFA TJP1 TGFB2 RS1 PLG PGF
28 kuhnt-junius degeneration 28.0 VEGFD VEGFC VEGFB VEGFA PLG PGF
29 hypertension, essential 27.9 VEGFC VEGFA PLG PGF KDR FLT1
30 macular degeneration, age-related, 1 27.2 VEGFD VEGFC VEGFB VEGFA TJP1 RS1
31 retinoschisis 1, x-linked, juvenile 11.7
32 central retinal vein occlusion 10.8
33 microvascular complications of diabetes 2 10.8
34 retinal ischemia 10.6
35 uveitis 10.5
36 bullous retinoschisis 10.5 VEGFA RS1
37 fuchs' heterochromic uveitis 10.5 TGFB2 CXCL8
38 blind hypotensive eye 10.4
39 preretinal fibrosis 10.4 VEGFA TGFB2
40 open-angle glaucoma 10.4
41 hypertensive encephalopathy 10.4 VEGFA PGF
42 severe nonproliferative diabetic retinopathy 10.4 VEGFA PGF
43 lipodermatosclerosis 10.4 VEGFA FLT1
44 glomeruloid hemangioma 10.4 VEGFA FLT1
45 yemenite deaf-blind hypopigmentation syndrome 10.4
46 upper lip cancer 10.4 TGFB2 FGF2
47 ocular hypertension 10.3
48 carotid stenosis 10.3
49 cancer-associated retinopathy 10.3 VEGFA PGF FLT1
50 interstitial cystitis 10.3 VEGFA TJP1 CXCL8

Graphical network of the top 20 diseases related to Neovascular Glaucoma:



Diseases related to Neovascular Glaucoma

Symptoms & Phenotypes for Neovascular Glaucoma

Human phenotypes related to Neovascular Glaucoma:

58 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 glaucoma 58 31 obligate (100%) Obligate (100%) HP:0000501
2 visual loss 58 31 hallmark (90%) Very frequent (99-80%) HP:0000572
3 retinal vein occlusion 58 31 hallmark (90%) Very frequent (99-80%) HP:0012636
4 iris neovascularization 58 31 hallmark (90%) Very frequent (99-80%) HP:0011497
5 photophobia 58 31 frequent (33%) Frequent (79-30%) HP:0000613
6 ocular pain 58 31 frequent (33%) Frequent (79-30%) HP:0200026
7 visual acuity test abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0030532
8 abnormality of the optic nerve 58 31 frequent (33%) Frequent (79-30%) HP:0000587
9 ocular hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0007906
10 abnormality of central retinal artery 58 31 frequent (33%) Frequent (79-30%) HP:3000032
11 retinal vascular proliferation 58 31 occasional (7.5%) Occasional (29-5%) HP:0007850
12 corneal stromal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0012040
13 abnormal anterior chamber morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0000593
14 retinal detachment 58 31 very rare (1%) Very rare (<4-1%) HP:0000541
15 abnormality of the posterior segment of the globe 58 Occasional (29-5%)
16 abnormality of the uvea 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Neovascular Glaucoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 FGF2 FLT1 KDR PGF PLG SLC6A13
2 cardiovascular system MP:0005385 10.06 FGF2 FLT1 KDR PGF PLG TGFB2
3 mortality/aging MP:0010768 9.93 CIAO3 FGF2 FLT1 KDR PLG TGFB2
4 nervous system MP:0003631 9.65 FGF2 FLT1 KDR PLG RS1 TGFB2
5 vision/eye MP:0005391 9.28 FGF2 FLT1 KDR PGF PLG RS1

Drugs & Therapeutics for Neovascular Glaucoma

Drugs for Neovascular Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Travoprost Approved Phase 4 157283-68-6 5282226
2
tannic acid Approved Phase 4 1401-55-4
3
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
4
Timolol Approved Phase 4 26839-75-8 33624 5478
5
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
6
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
7
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
8
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
9
Brinzolamide Approved Phase 4 138890-62-7 68844
10 Anesthetics Phase 4
11 Antibodies, Monoclonal Phase 4
12 Antibodies Phase 4
13 Immunoglobulins Phase 4
14 Antineoplastic Agents, Immunological Phase 4
15 Pharmaceutical Solutions Phase 4
16 Adrenergic beta-Antagonists Phase 4
17 Ophthalmic Solutions Phase 4
18 Carbonic Anhydrase Inhibitors Phase 4
19 Brimonidine Tartrate Phase 4 70359-46-5
20
Ranibizumab Approved Phase 3 347396-82-1 459903
21
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
24 insulin Phase 2, Phase 3
25 Insulin, Globin Zinc Phase 2, Phase 3
26 Angiogenesis Inhibitors Phase 2, Phase 3
27 Mitomycins Phase 2, Phase 3
28 Hormone Antagonists Phase 2, Phase 3
29 Immunologic Factors Phase 2, Phase 3
30 triamcinolone acetonide Phase 2, Phase 3
31 Anti-Inflammatory Agents Phase 2, Phase 3
32 Triamcinolone diacetate Phase 2, Phase 3
33 Triamcinolone hexacetonide Phase 2, Phase 3
34 glucocorticoids Phase 2, Phase 3
35 Immunosuppressive Agents Phase 2, Phase 3
36 Hormones Phase 2, Phase 3
37 Anti-Bacterial Agents Phase 2, Phase 3
38 Alkylating Agents Phase 2, Phase 3
39 Antibiotics, Antitubercular Phase 2, Phase 3
40 BB 1101 Phase 2, Phase 3
41 Antimetabolites Phase 2, Phase 3
42 Gentamicins Phase 2, Phase 3
43 Endothelial Growth Factors Phase 3
44 Mitogens Phase 3
45
Bevacizumab Approved, Investigational Phase 2 216974-75-3
46
Epinephrine Approved, Vet_approved 51-43-4 5816
47
Racepinephrine Approved 329-65-7 838
48
Emodepside Investigational, Vet_approved 155030-63-0
49 Epinephryl borate

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
2 Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment Unknown status NCT02594423 Phase 4 Bevacizumab
3 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
4 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4 intravitreal ranibizumab
5 The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion Completed NCT00557232 Phase 4 bevacizumab
6 Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves Recruiting NCT01535768 Phase 4 Aqueous Suppressant Eye Drops
7 Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Unknown status NCT02914626 Phase 3 Intravitreal ranibizumab
8 Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma Unknown status NCT02947867 Phase 2, Phase 3 aganirsen
9 Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma: a Randomized Controlled Clinical Trial Unknown status NCT01128699 Phase 3 Subconjunctival Avastin
10 A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma Completed NCT02396316 Phase 3 Aflibercept (Eylea, BAY 86-5321);Sham Injection
11 A Single-arm, Non-randomized and Open-label Phase 3 Study Evaluating the Efficacy, Safety and Tolerability of Intravitreal Aflibercept in Japanese Patients With Neovascular Glaucoma (NVG) Completed NCT03639675 Phase 3 Aflibercept (EYLEA, BAY86-5321);Topical IOP-lowering drugs
12 The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery Completed NCT00853905 Phase 2, Phase 3 Triesence;balanced salt solution BSS
13 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed NCT01908816 Phase 3 ranibizumab
14 Comprative Study of the Safety and Effectiveness Between Oculusgen (Ologen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery Completed NCT00524758 Phase 3 MMC in Trabeculectomy
15 Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis Completed NCT02641457 Phase 3 Aflibercept;Ranibizumab
16 Central Vein Occlusion Study (CVOS) Completed NCT00000131 Phase 3
17 Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
18 An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
19 Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma: A Randomized Pilot Trial. Completed NCT02901236 Phase 2, Phase 3 Mitomycin C;Bevacizumab
20 Randomized Trial Evaluating Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema Completed NCT02985619 Phase 2, Phase 3 Bevacizumab;Triamcinolone Acetonide
21 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
22 Analysis of Vitreous and Aqueous Humor for Ocular Growth Factors, Cytokines, Chemokines, and Ranibizumab Pharmacokinetics Associated With Various Retinal Disease Unknown status NCT02067013 Phase 2 Ranibizumab
23 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
24 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Patients With Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
25 Does Hyperbaric Chamber Improve the Functionality and Symptoms Related to Central Retinal Vein Occlusion (CRVO)? Unknown status NCT02405741 Phase 2
26 Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma Completed NCT01051583 Phase 2
27 Lucentis in the Treatment of Macular Edema - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab Versus Focal Laser Treatment in Subjects With Diabetic Macular Edema Completed NCT00387582 Phase 2 Ranibizumab (Lucentis)
28 Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study Recruiting NCT02486484 Phase 2 ziv-aflibercept
29 Ahmed Glaucoma Valve Surgery With Mitomycin-C Active, not recruiting NCT02805257 Phase 2 Mitomycin-C
30 Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma Withdrawn NCT00727038 Phase 1, Phase 2 Ranibizumab (Lucentis)
31 A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Completed NCT00765921 Phase 1 ranibizumab
32 Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion Completed NCT00406471 Phase 1 Ranibizumab (Lucentis)
33 A Phase I Open Label Study of the Safety, Tolerability and Efficacy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Terminated NCT01225146 Phase 1 ranibizumab
34 Comparative Study of the Safety and Efficacy of the Ahmed Glaucoma Valve Drainage Device, Model M4 (High Density Porous Polyethylene) and the Model S2 (Polypropylene) in Patients With Neovascular Glaucoma Unknown status NCT02260219
35 Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection Unknown status NCT00491712
36 Comparative,Randomized Study Between Intravitreal Triamcinolone Acetonide and Air-Fluid Exchange in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage Unknown status NCT00300014
37 Adjunctive Triamcinolone Acetonide for Ahmed Glaucoma Valve Implantation Unknown status NCT02653963 Adjunctival Triamcinolone
38 Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial Completed NCT00384631 Avastin
39 An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma Completed NCT01370135 0.5mg intraocular Ranibizumab (Lucentis)
40 The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma Completed NCT03154892
41 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma Completed NCT01711879 Aflibercept
42 Triple Procedure for Dense Cataractus Neovascular Glaucoma Patients Completed NCT04143620
43 Clinical Trial Comparing Subconjunctival and Topical Bevacizumab as Adjuncts to Trabeculectomy in Improving Outcomes for Primary Open Angle Glaucoma Completed NCT01425112
44 Compliance to Ophthalmic Follow-up Examinations Affect Outcome of Vitrectomy for Proliferative Diabetic Retinopathy Completed NCT01307072
45 Bevacizumab (Avastin) as an Adjunct to Vitrectomy in the Management of Severe Proliferative Diabetic Retinopathy: a Prospective Case Series Completed NCT01041690 Bevacizumab
46 Objective Measurement of Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With a Vascular Endothelial Growth Factor Inhibitor. Completed NCT01360385
47 A Randomized Trial of the Pops-titration Versus the Slow-coagulation Energy Delivery Technique on the Outcome of Diode Laser Transcleral Cyclophotocoagulation in Treatment of Refractory Glaucoma With Dark Iris Completed NCT01774227
48 Optic Nerve Compliance Study Completed NCT00328835
49 Randomized, Controlled Trial in Patients With Senile Cataract to Evaluate the Efficacy of Ultrasound-free Femtosecond Laser (FLACS) Cataract Surgery (USFREE), Compared to Traditional Phacoemulsification Surgery Using Ultrasound. Completed NCT03050008
50 The Ahmed Versus Baerveldt (AVB) Study: Prospective, Multicenter Trial Comparing the Ahmed-FP7 Valve With the Baerveldt-350 Implant in Treating Refractory Glaucoma Completed NCT00940823

Search NIH Clinical Center for Neovascular Glaucoma

Cochrane evidence based reviews: glaucoma, neovascular

Genetic Tests for Neovascular Glaucoma

Anatomical Context for Neovascular Glaucoma

MalaCards organs/tissues related to Neovascular Glaucoma:

40
Eye, Endothelial, B Cells, Retina, Myeloid, Lung, Breast

Publications for Neovascular Glaucoma

Articles related to Neovascular Glaucoma:

(show top 50) (show all 1566)
# Title Authors PMID Year
1
Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients. 54 61
20373895 2010
2
Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. 54 61
19794946 2009
3
Level of vascular endothelial growth factor in aqueous humor and surgical results of ahmed glaucoma valve implantation in patients with neovascular glaucoma. 54 61
19680051 2009
4
Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. 54 61
18617542 2009
5
Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. 54 61
17700285 2007
6
[The change of the level of the vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma before and after anterior retinal cryotherapy]. 54 61
17897552 2007
7
[Inhibition of angiogenesis in the anterior chamber of the eye]. 54 61
17372736 2007
8
Increased levels of transforming growth factor-betal and -beta2 in the aqueous humor of patients with neovascular glaucoma. 54 61
17278530 2007
9
Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. 54 61
17004630 2006
10
Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. 54 61
12362079 2002
11
[Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma]. 54 61
9852717 1998
12
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. 54 61
9479280 1998
13
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. 54 61
8694732 1996
14
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. 61
31708274 2020
15
Anti-vascular endothelial growth factor for neovascular glaucoma. 61
32027392 2020
16
Altered Intrinsic Functional Connectivity of the Primary Visual Cortex in Patients with Neovascular Glaucoma: A Resting-State Functional Magnetic Resonance Imaging Study. 61
32021196 2020
17
Immunohistochemical and Immunocytochemical Analyses in Patients with Vitreoretinal Lymphoma. 61
30335535 2020
18
Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy. 61
32005066 2020
19
Orbital Diffuse Large B-Cell Lymphoma Initially Presenting as Neovascular Glaucoma. 61
31593042 2020
20
Bariatric surgery might aggravate proliferative diabetic retinopathy. 61
31912621 2020
21
Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors. 61
31688338 2020
22
Comment on: Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. 61
32005485 2020
23
Comment on: Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. 61
31733688 2020
24
Retinal and Choroidal Vascular Changes in Eyes with Pseudoexfoliation Syndrome: A Comparative Study Using Optical Coherence Tomography Angiography 61
31594281 2019
25
Needling with 5-fluorouracil for encapsulated blebs after Ahmed glaucoma valve implantation. 61
31362526 2019
26
Increased expression of periostin and tenascin-C in eyes with neovascular glaucoma secondary to PDR. 61
31863397 2019
27
Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. 61
31802372 2019
28
Preservation of retinoblastoma group E eyes with neovascular glaucoma using intravenous chemotherapy: risk factors and outcomes. 61
30796055 2019
29
Large B-cell lymphoma of the uvea: Histopathologic variants and clinicopathologic correlation. 61
31676312 2019
30
Early vitrectomy combined with pan retinal photocoagulation, anti-vascular endothelial growth factor, and gradual cyclophotocoagulation for treatment of neovascular glaucoma. 61
31613817 2019
31
Effect of Pars Plana Vitrectomy With or Without Cataract Surgery in Patients with Diabetes: A Systematic Review and Meta-Analysis. 61
31347099 2019
32
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study. 61
30877707 2019
33
Histopathologic findings after selective ophthalmic arterial injection of melphalan for retinoblastoma. 61
31942432 2019
34
Risk Factors of Neovascular Glaucoma After 25-gauge Vitrectomy for Proliferative Diabetic Retinopathy with Vitreous Hemorrhage: A Retrospective Multicenter Study. 61
31619708 2019
35
Predictors of enucleation in Coats disease: analysis of 259 eyes of 259 patients at a single center. 61
31521848 2019
36
Neutrophil-To-Lymphocyte Ratio as a Potential Biomarker of Neovascular Glaucoma. 61
31671021 2019
37
Frequency and Risk Factors for Neovascular Glaucoma After Vitrectomy in Eyes with Diabetic Retinopathy: An Observational Study. 61
31321746 2019
38
Comparison of Erythropoietin, Semaphorins 3A and Pigment Epithelium Derived Factor Levels in Serum and Aqueous Humor of Patients with Neovascular Glaucoma and Cataract. 61
31455493 2019
39
Chronic myeloid leukaemia accelerates proliferative retinopathy in patients with co-existent diabetes: A risk factor not to be ignored. 61
31514533 2019
40
Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. 61
31277883 2019
41
Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. 61
31300151 2019
42
[Intravitreal angiostatic treatment of ocular vascular diseases]. 61
31538583 2019
43
Late re-activation of Coats disease. 61
31193172 2019
44
Ocular Manifestations of von Hippel-Lindau Disease. 61
31588386 2019
45
Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions. 61
30878488 2019
46
Outcomes of Wider Area Bleb Revision Using Bleb Knife With Adjunctive Mitomycin C. 61
31135591 2019
47
Iodine-125 Episcleral Plaque Brachytherapy for AJCC T4 Posterior Uveal Melanoma: Clinical Outcomes in 158 Patients. 61
31559245 2019
48
Glaucoma incidence risk in a cohort of Mayak PA workers occupationally exposed to ionizing radiation. 61
31462740 2019
49
Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. 61
30862502 2019
50
Rituximab-Associated Retinal Occlusive Vasculopathy: A Case Report and Literature Review. 61
31314626 2019

Variations for Neovascular Glaucoma

Expression for Neovascular Glaucoma

Search GEO for disease gene expression data for Neovascular Glaucoma.

Pathways for Neovascular Glaucoma

Pathways related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 VEGFD VEGFC VEGFB VEGFA TGFB2 PGF
2
Show member pathways
13.82 VEGFD VEGFC VEGFB TGFB2 PLG PGF
3
Show member pathways
13.69 VEGFD VEGFC VEGFB VEGFA TGFB2 PGF
4
Show member pathways
13.57 VEGFD VEGFC VEGFB VEGFA TGFB2 PGF
5
Show member pathways
13.54 VEGFD VEGFC VEGFB TGFB2 PGF KDR
6
Show member pathways
13.44 VEGFD VEGFC VEGFB TGFB2 PGF KDR
7
Show member pathways
13.34 VEGFD VEGFC VEGFB TGFB2 PGF KDR
8
Show member pathways
13.31 VEGFD VEGFC VEGFB TJP1 TGFB2 PGF
9
Show member pathways
13.29 VEGFD VEGFC VEGFB VEGFA TGFB2 PGF
10
Show member pathways
13.1 VEGFD VEGFC VEGFB TGFB2 PGF KDR
11
Show member pathways
13.08 VEGFD VEGFC VEGFB TGFB2 PGF KDR
12
Show member pathways
13.02 VEGFD VEGFC VEGFB VEGFA PGF KDR
13
Show member pathways
12.95 VEGFD VEGFC VEGFB VEGFA PGF KDR
14 12.88 VEGFD VEGFC VEGFB VEGFA TGFB2 PGF
15
Show member pathways
12.76 VEGFD VEGFC VEGFB VEGFA PGF KDR
16
Show member pathways
12.68 VEGFD VEGFC VEGFB TGFB2 PGF KDR
17 12.48 VEGFD VEGFC VEGFB VEGFA TGFB2 PGF
18
Show member pathways
12.45 VEGFD VEGFC VEGFB VEGFA PGF KDR
19
Show member pathways
12.42 VEGFD VEGFC VEGFB TGFB2 PGF KDR
20
Show member pathways
12.42 VEGFD VEGFC VEGFB VEGFA KDR FLT1
21
Show member pathways
12.3 VEGFC VEGFB VEGFA KDR FLT1 FGF2
22 12.29 VEGFA TGFB2 KDR FGF2
23 12.19 VEGFC VEGFB KDR FLT1 FGF2
24
Show member pathways
11.93 VEGFA KDR FLT1
25 11.92 VEGFA FGF2 CXCL8
26 11.92 VEGFA TGFB2 FLT1 CXCL8
27 11.88 VEGFD VEGFC VEGFB VEGFA TGFB2 CXCL8
28
Show member pathways
11.82 VEGFD VEGFC VEGFB TGFB2 PGF KDR
29 11.79 VEGFD VEGFC VEGFB TGFB2 PGF FGF2
30
Show member pathways
11.76 VEGFC VEGFB VEGFA PGF KDR FLT1
31 11.71 VEGFA TGFB2 KDR FLT1
32 11.68 VEGFC VEGFB TGFB2 KDR FLT1 FGF2
33 11.67 VEGFA TGFB2 FGF2
34 11.66 VEGFD VEGFC VEGFB VEGFA
35 11.57 VEGFA TGFB2 PLG KDR FGF2
36 11.51 VEGFA KDR FGF2
37 11.51 VEGFC VEGFB VEGFA
38 11.46 VEGFB VEGFA KDR FLT1 FGF2
39 11.37 VEGFA KDR FLT1
40 11.26 VEGFA KDR FLT1 FGF2
41 11.25 VEGFA FLT1 FGF2
42 10.92 VEGFD VEGFC VEGFB TGFB2 PGF KDR
43 10.74 VEGFC VEGFB VEGFA
44
Show member pathways
10.37 VEGFD VEGFC VEGFB VEGFA PGF KDR

GO Terms for Neovascular Glaucoma

Cellular components related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 VEGFD VEGFC VEGFB VEGFA TGFB2 RS1
2 extracellular region GO:0005576 9.73 VEGFD VEGFC VEGFB VEGFA TGFB2 RS1
3 platelet alpha granule lumen GO:0031093 9.1 VEGFD VEGFC VEGFB VEGFA TGFB2 PLG

Biological processes related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.17 VEGFD VEGFC VEGFA RS1 PGF KDR
2 cell differentiation GO:0030154 10.14 VEGFD VEGFC VEGFA PGF KDR FLT1
3 positive regulation of cell proliferation GO:0008284 10.13 VEGFD VEGFC VEGFA TGFB2 PGF KDR
4 response to hypoxia GO:0001666 10.08 VEGFD VEGFC VEGFB VEGFA UCP2 TGFB2
5 positive regulation of protein phosphorylation GO:0001934 10.01 VEGFD VEGFC VEGFB VEGFA PGF KDR
6 positive regulation of endothelial cell proliferation GO:0001938 10 VEGFD VEGFC VEGFB VEGFA PGF KDR
7 platelet degranulation GO:0002576 9.99 VEGFD VEGFC VEGFB VEGFA TGFB2 PLG
8 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.98 VEGFD VEGFC VEGFB VEGFA PGF KDR
9 response to drug GO:0042493 9.97 VEGFC VEGFB TJP1 TGFB2 PGF
10 positive chemotaxis GO:0050918 9.97 VEGFD VEGFC VEGFB VEGFA PGF FGF2
11 positive regulation of cell division GO:0051781 9.91 VEGFD VEGFC VEGFB VEGFA TGFB2 PGF
12 positive regulation of angiogenesis GO:0045766 9.91 VEGFD VEGFC VEGFB VEGFA PGF KDR
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.85 VEGFC VEGFA KDR FGF2
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 TGFB2 KDR FLT1
15 positive regulation of mast cell chemotaxis GO:0060754 9.8 VEGFD VEGFC VEGFB VEGFA PGF
16 induction of positive chemotaxis GO:0050930 9.8 VEGFD VEGFC VEGFB VEGFA PGF CXCL8
17 positive regulation of MAP kinase activity GO:0043406 9.79 VEGFA FLT1 FGF2
18 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.77 VEGFA KDR FGF2
19 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.76 VEGFA KDR FLT1
20 cell migration involved in sprouting angiogenesis GO:0002042 9.73 VEGFA KDR FGF2
21 sprouting angiogenesis GO:0002040 9.7 VEGFD VEGFC VEGFB VEGFA PGF KDR
22 angiogenesis GO:0001525 9.65 VEGFD VEGFC VEGFB VEGFA TGFB2 PGF
23 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.64 VEGFA FLT1
24 embryonic digestive tract development GO:0048566 9.64 TGFB2 CXCL8
25 positive regulation of phospholipase C activity GO:0010863 9.63 FLT1 FGF2
26 positive regulation of positive chemotaxis GO:0050927 9.62 VEGFA KDR
27 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.62 VEGFA PLG
28 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.61 VEGFA KDR
29 vascular endothelial growth factor signaling pathway GO:0038084 9.17 VEGFD VEGFC VEGFB VEGFA PGF KDR

Molecular functions related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.76 VEGFA TGFB2 FGF2 CXCL8
2 growth factor activity GO:0008083 9.7 VEGFD VEGFC VEGFB VEGFA TGFB2 PGF
3 heparin binding GO:0008201 9.67 VEGFB VEGFA PGF FGF2
4 platelet-derived growth factor receptor binding GO:0005161 9.48 VEGFD VEGFA
5 vascular endothelial growth factor binding GO:0038085 9.43 KDR FLT1
6 chemoattractant activity GO:0042056 9.43 VEGFD VEGFC VEGFB VEGFA PGF FGF2
7 vascular endothelial growth factor-activated receptor activity GO:0005021 9.4 KDR FLT1
8 vascular endothelial growth factor receptor 1 binding GO:0043183 9.32 VEGFB VEGFA
9 vascular endothelial growth factor receptor 3 binding GO:0043185 9.26 VEGFD VEGFC
10 vascular endothelial growth factor receptor binding GO:0005172 9.02 VEGFD VEGFC VEGFB VEGFA PGF

Sources for Neovascular Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....